Is bisphosphonate therapy a risk factor for subtrochanteric femoral fractures?

David B. Burr

Research output: Contribution to journalShort survey

1 Scopus citations


The rate of bone turnover in the femoral shaft is normally quite low. In some patients being treated with alendronate, the remodeling rate may have been excessively low. This suggests that before a patient is given a bisphosphonate, biomarkers related to bone resorption and formation should be measured.

Original languageEnglish (US)
Pages (from-to)57-58
Number of pages2
JournalJournal of the American Academy of Orthopaedic Surgeons
Issue number1
StatePublished - Jan 1 2009


ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this